Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.93, $0.17 better than the analyst estimate of $0.76. Revenue for the quarter came in at $5.5 billion versus the consensus estimate of $5.31 billion.

GUIDANCE:

Teva Pharma sees FY2018 EPS of $2.25-$2.50, versus the consensus of $2.94. Teva Pharma sees FY2018 revenue of $18.3-18.8 billion, versus the consensus of $19.26 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Workhorse Group (WKHS) Misses Q2 EPS by 77c
• Cheetah Net Supply Chain Service Inc. (CTNT) Reports Q2 EPS of $0.04